Our research in Immunology
Intended for healthcare professionals, scientific audiences and media.
Pursuing pathbreaking science in Immunology
Hear from our Board Chair and CEO, Giovanni Caforio, M.D., about our commitment to elevating patient care to new standards to deliver what matters most – the promise of living a better life.
At Bristol Myers Squibb, we are working to deliver meaningful solutions that address unmet needs in rheumatology, gastroenterology, dermatology and neurology. While there has been progress with medicines for immune-mediated diseases, people living with these conditions may not respond to available treatments. Many continue to endure chronic symptoms and disease progression that can take a toll on their daily life.
Our goal is to restore some of what immune-mediated diseases have taken away — empowering patients and their loved ones to take back their lives.
Our scientific innovation
Bristol Myers Squibb is focused on delivering scientific innovation with the empathy and urgency needed to advance care for people living with immune-mediated diseases.
As we continuously build and expand our portfolio, our teams work to identify mechanisms that may reset and promote balance in the immune system, with the goal of achieving long-term remission and, ultimately, curative therapies.
Hear from Jonathan Sadeh, MD, MSc, senior vice president of Immunology and Fibrosis Development at Bristol Myers Squibb, about how the company aims to build a robust immunology portfolio with pathbreaking science that addresses the unmet needs of people living with immune-mediated diseases.
Meet our Immunology researchers
Our presence at upcoming conferences
April 8-10, 2022
May 6-10, 2022
May 12-15, 2022
Congress of Clinical Rheumatology East
October 5-8, 2022
13th European Lupus Meeting 2022
October 20-23, 2022
Congress of Clinical Rheumatology West
November 1-6, 2022
American Society of Nephrology (ASN) Kidney Week 2022
November 10-14, 2022
American College of Rheumatology (ACR) Convergence 2022
May 21-24, 2022
Digestive Disease Week (DDW) 2022
October 8-11, 2022
United European Gastroenterology (UEG) Week
October 21-26, 2022
American College of Gastroenterology (ACG) 2022
December 5-7 2022
Advances in Inflammatory Bowel Diseases (AIBD) 2022
March 25-29, 2022
2022 American Academy of Dermatology (AAD) Annual Meeting
April 9-11, 2022
4th Annual Revolutionizing Atopic Dermatitis Conference
June 22-25, 2022
Maui Derm NP+PA Summer 2022
July 28-31, 2022
September 7-10, 2022
31st EADV Congress
September 18-21, 2022
Maui Derm NP+PA Fall 2022
September 20-23, 2022
September 28-October 1, 2022
51st Annual European Society for Dermatological Research (ESDR) Meeting
October 17-19, 2022
12th International Symposium on Atopic Dermatitis (ISAD)
October 20-23, 2022
November 17-20, 2022
SDPA 20th Annual Fall Dermatology Conference
April 2-7, 2022 Seattle | April 24-26, 2022 Virtual
American Academy of Neurology (AAN) Annual Meeting
June 25-28, 2022
European Academy of Neurology (EAN) Congress
November 17-19, 2022
European Charcot Foundation 30th Annual Meeting
Every day, each of us works to improve outcomes for patients fighting serious immune-mediated diseases. We're creative thinkers motivated by the practical application of our work, and innovators unafraid to step into uncharted territory. Together, we're building a better future for each other and the patients who need us most.
Over 20 years ago, Bristol Myers Squibb pioneered the science of modulating the body’s immune response to treat disease, beginning with the company’s research in rheumatoid arthritis (RA). Building on that foundation, we continue to pursue pathbreaking science across rheumatic diseases including RA, psoriatic arthritis, lupus and ankylosing spondylitis. Fueled by the possibility to help more patients, we are following the science to tailor therapies to individual needs, improve outcomes and expand treatment options.
The European Congress of Rheumatology 2022 (EULAR 2022) represents an important touchpoint to communicate the latest scientific breakthroughs and foster scientific exchange with the rheumatology research and medical community. Bristol Myers Squibb is looking forward to sharing 21 company-sponsored presentations, which include clinical and health economics and outcomes research (HEOR) data across rheumatoid arthritis, lupus, psoriatic arthritis, psoriasis and juvenile idiopathic arthritis. Findings include positive late-breaking data in systemic lupus erythematosus and research that further showcases the strength and depth of our robust pipeline. Together, our data continue to demonstrate our commitment to pursuing innovative science to address unmet needs for people living with rheumatic diseases.
Subhashish Banerjee, MD, vice president & disease area head, Rheumatology and Dermatology at Bristol Myers Squibb, shares how the company is leveraging a pathways-based approach to advance research and ultimately elevate care for patients in need of new treatment options in systemic lupus erythematosus (SLE), also known as lupus.
Bristol Myers Squibb is pursuing innovative research to potentially change the course of gastrointestinal immune-mediated diseases, including inflammatory bowel disease (IBD) (which includes ulcerative colitis and Crohn's disease) and eosinophilic esophagitis (EoE). Our scientific innovations have the potential to provide relief and remission to people living with these conditions.
Through Bristol Myers Squibb’s pioneering exploration of immune pathways implicated in dermatologic conditions, our discovery team’s research is leading to the potential for safe, effective, category-defining new therapies that may address the pressing treatment gaps that continue to exist for people living with these conditions. With a highly focused pipeline, we are pursuing novel treatments for psoriasis and atopic dermatitis and exploring a broad range of serious dermatologic conditions in our early research.
At Bristol Myers Squibb, we are focused on delivering solutions that may help preserve physical and cognitive function in people living with neurological conditions like multiple sclerosis (MS). Building on our experience, we are pursuing pathbreaking science to improve care for those impacted by the disease. By helping restore some of what MS has taken away, we aim to empower people living with MS and their loved ones to take back control of their lives.
The 2022 European Association of Neurology (EAN) annual meeting represents an important opportunity for scientific exchange that can benefit patients and the neurology research community. Bristol Myers Squibb looks forward to sharing five company-sponsored presentations at this year's meeting. These presentations demonstrate the company's commitment to advancing pathbreaking science for patients living with immune-mediated diseases, such as relapsing multiple sclerosis.